SGLT2阻害薬市場 - 世界の産業規模、シェア、動向、機会、予測：薬剤別（ジャディアンス、ファーミガ、インペファ、インボカーナ、その他）、適応症別（2型糖尿病、心血管、その他）、地域別、競合別、2020年～2030年

世界のSGLT2阻害薬市場は、2024年に153億7,000万米ドルと評価され、CAGR 5.90％で2030年には214億4,000万米ドルに達すると予測されています。

これらの経口糖尿病治療薬は、腎臓からのグルコース排泄を促進することで血糖値を低下させ、同時に体重減少や心血管リスク低減などのその他の特典も得られるため、好ましい治療選択肢として浮上しています。

糖尿病罹患率の上昇に加え、血糖コントロール不良に伴う合併症に対する意識の高まりにより、効果的で忍容性の高い治療オプションを求める患者層が拡大しています。堅調な成長が見込まれるもの、高額な治療費、厳しい規制要件、尿路感染症やケトアシドーシスなどの副作用に対する懸念といった課題が、市場の拡大をある程度抑制する可能性があります。

主な市場促進要因

ヘルスケア産業の成長

主な市場課題

治療費の高騰

主な市場動向

糖尿病の有病率の上昇

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 COVID-19が世界のSGLT2阻害薬市場に与える影響

第5章 世界のSGLT2阻害薬市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 薬剤別（ジャディアンス、ファーミガ、インペファ、インボカーナ、その他）
  • 適応症別（2型糖尿病、心血管疾患、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米のSGLT2阻害薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • メキシコ
  • カナダ

第7章 欧州のSGLT2阻害薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • フランス
  • ドイツ
  • 英国
  • イタリア
  • スペイン

第8章 アジア太平洋地域のSGLT2阻害薬市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 韓国
  • 日本
  • オーストラリア

第9章 南米のSGLT2阻害薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのSGLT2阻害薬市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 合併と買収
• 製品上市
• 最近の動向

第13章 混乱：紛争、パンデミック、貿易障壁

第14章 世界のSGLT2阻害薬市場：SWOT分析

第15章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第16章 競合情勢

• Boehringer Ingelheim International GmbH
• AstraZeneca
• Merck & Co., Inc.
• Janssen Pharmaceuticals, Inc.
• TheracosBio, LLC
• Lexicon Pharmaceuticals, Inc.
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Glenmark Pharmaceuticals Ltd.

第17章 戦略的提言

第18章 調査会社について・免責事項

Global SGLT2 Inhibitors Market was valued at USD 15.37 Billion in 2024 and is expected to reach USD 21.44 Billion by 2030 with a CAGR of 5.90%. These oral antidiabetic agents have emerged as a preferred therapeutic option due to their ability to lower blood glucose levels by promoting glucose excretion through the kidneys, while also offering additional benefits such as weight loss and cardiovascular risk reduction.

Rising diabetes incidence, coupled with growing awareness of the complications associated with poor glycemic control, has led to an expanding patient pool demanding effective and well-tolerated treatment options. Despite robust growth prospects, challenges such as high treatment costs, stringent regulatory requirements, and concerns about side effects including urinary tract infections and ketoacidosis may constrain market expansion to some extent.

Key Market Drivers

Growth in Healthcare Industry

The rapid expansion of the global healthcare industry is a significant catalyst driving growth in the SGLT2 inhibitors market. The global healthcare industry generates annual sales exceeding USD 4 trillion. Its largest and most lucrative segments are pharmaceuticals and biotechnology, with revenues approaching USD 850 billion, followed by medical technology and diagnostics, which exceed USD 400 billion. Increasing investments in healthcare infrastructure, advancements in medical technology, and improved access to quality care are collectively enhancing the diagnosis and management of chronic diseases such as type 2 diabetes mellitus (T2DM), which is the primary indication for SGLT2 inhibitors.

Rising healthcare expenditure, particularly in emerging economies, is enabling broader patient access to innovative therapies, including SGLT2 inhibitors. A report from the World Health Organization (WHO) indicates that global health expenditure continued to rise in 2021, the second year of the pandemic, reaching USD 9.8 trillion equivalent to 10.3% of global GDP. This increase was primarily driven by higher government funding and out-of-pocket expenses. Furthermore, the growing emphasis on early diagnosis and comprehensive disease management programs is boosting prescription rates for these novel antidiabetic agents.

Key Market Challenges

High Cost of Therapy

One of the primary challenges facing the global SGLT2 inhibitors market is the high cost of therapy, which can limit patient access and hinder widespread adoption. Despite their proven clinical benefits, SGLT2 inhibitors are often priced at a premium compared to traditional antidiabetic medications, placing a significant financial burden on both patients and healthcare systems, particularly in low- and middle-income countries.

The elevated cost is driven by factors such as complex manufacturing processes, ongoing research and development expenditures, and patent protections that limit the availability of lower-cost generic alternatives. This pricing barrier may result in restricted insurance coverage or reimbursement limitations, thereby reducing affordability for a large segment of the diabetic population.

Key Market Trends

Rising Prevalence of Diabetes

The escalating prevalence of diabetes, particularly type 2 diabetes mellitus (T2DM), is a critical trend shaping the trajectory of the global SGLT2 inhibitors market. According to recent epidemiological data, the number of individuals diagnosed with diabetes continues to rise worldwide, driven by factors such as sedentary lifestyles, urbanization, obesity, and aging populations.

Diabetes statistics highlight the increasing global burden of the disease on individuals, families, and nations. According to the latest International Diabetes Federation (IDF) Diabetes Atlas (2025), 11.1% or 1 in 9 of adults aged 20-79 are living with diabetes, with more than 40% unaware of their condition. This growing patient pool has intensified the demand for effective and innovative therapeutic options, positioning SGLT2 inhibitors as a preferred class of oral antidiabetic agents. Their ability to improve glycemic control, coupled with additional benefits such as cardiovascular and renal protection, has enhanced their clinical appeal and expanded their use.

Key Market Players

• Boehringer Ingelheim International GmbH
• AstraZeneca
• Merck & Co., Inc.
• Janssen Pharmaceuticals, Inc.
• TheracosBio, LLC
• Lexicon Pharmaceuticals, Inc.
• Eli Lilly and Company
• Bristol-Myers Squibb Company
• Glenmark Pharmaceuticals Ltd.

Report Scope

In this report, the Global SGLT2 Inhibitors Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

SGLT2 Inhibitors Market, By Drug:

• Jardiance
• Farmiga
• Inpefa
• Invokana
• Others

SGLT2 Inhibitors Market, By Indication:

• Type 2 Diabetes
• Cardiovascular
• Others

SGLT2 Inhibitors Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global SGLT2 Inhibitors Market.

Available Customizations:

Global SGLT2 Inhibitors Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, and Trends

4. Impact of COVID-19 on Global SGLT2 Inhibitors Market

5. Global SGLT2 Inhibitors Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug (Jardiance, Farmiga, Inpefa, Invokana, Others)
  • 5.2.2. By Indication (Type 2 Diabetes, Cardiovascular, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America SGLT2 Inhibitors Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug
  • 6.2.2. By Indication
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States SGLT2 Inhibitors Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug
      • 6.3.1.2.2. By Indication
  • 6.3.2. Mexico SGLT2 Inhibitors Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug
      • 6.3.2.2.2. By Indication
  • 6.3.3. Canada SGLT2 Inhibitors Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug
      • 6.3.3.2.2. By Indication

7. Europe SGLT2 Inhibitors Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug
  • 7.2.2. By Indication
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France SGLT2 Inhibitors Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug
      • 7.3.1.2.2. By Indication
  • 7.3.2. Germany SGLT2 Inhibitors Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug
      • 7.3.2.2.2. By Indication
  • 7.3.3. United Kingdom SGLT2 Inhibitors Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug
      • 7.3.3.2.2. By Indication
  • 7.3.4. Italy SGLT2 Inhibitors Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug
      • 7.3.4.2.2. By Indication
  • 7.3.5. Spain SGLT2 Inhibitors Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug
      • 7.3.5.2.2. By Indication

8. Asia Pacific SGLT2 Inhibitors Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug
  • 8.2.2. By Indication
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China SGLT2 Inhibitors Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug
      • 8.3.1.2.2. By Indication
  • 8.3.2. India SGLT2 Inhibitors Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug
      • 8.3.2.2.2. By Indication
  • 8.3.3. South Korea SGLT2 Inhibitors Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug
      • 8.3.3.2.2. By Indication
  • 8.3.4. Japan SGLT2 Inhibitors Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug
      • 8.3.4.2.2. By Indication
  • 8.3.5. Australia SGLT2 Inhibitors Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug
      • 8.3.5.2.2. By Indication

9. South America SGLT2 Inhibitors Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug
  • 9.2.2. By Indication
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil SGLT2 Inhibitors Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug
      • 9.3.1.2.2. By Indication
  • 9.3.2. Argentina SGLT2 Inhibitors Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug
      • 9.3.2.2.2. By Indication
  • 9.3.3. Colombia SGLT2 Inhibitors Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug
      • 9.3.3.2.2. By Indication

10. Middle East and Africa SGLT2 Inhibitors Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug
  • 10.2.2. By Indication
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa SGLT2 Inhibitors Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug
      • 10.3.1.2.2. By Indication
  • 10.3.2. Saudi Arabia SGLT2 Inhibitors Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug
      • 10.3.2.2.2. By Indication
  • 10.3.3. UAE SGLT2 Inhibitors Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug
      • 10.3.3.2.2. By Indication

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Disruptions: Conflicts, Pandemics and Trade Barriers

14. Global SGLT2 Inhibitors Market: SWOT Analysis

15. Porters Five Forces Analysis

• 15.1. Competition in the Industry
• 15.2. Potential of New Entrants
• 15.3. Power of Suppliers
• 15.4. Power of Customers
• 15.5. Threat of Substitute Products

16. Competitive Landscape

• 16.1. Boehringer Ingelheim International GmbH
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (As Reported)
  • 16.1.5. Recent Developments
  • 16.1.6. Key Personnel Details
  • 16.1.7. SWOT Analysis
• 16.2. AstraZeneca
• 16.3. Merck & Co., Inc.
• 16.4. Janssen Pharmaceuticals, Inc.
• 16.5. TheracosBio, LLC
• 16.6. Lexicon Pharmaceuticals, Inc.
• 16.7. Eli Lilly and Company
• 16.8. Bristol-Myers Squibb Company
• 16.9. Glenmark Pharmaceuticals Ltd.

17. Strategic Recommendations

18. About Us & Disclaimer